社保违规、海外布局遇挫，钛和检测募资海外扩张合理性存疑

Core Viewpoint - Recently, Tihe Testing and Certification Group Co., Ltd. submitted a listing application to the Hong Kong Stock Exchange, aiming to raise funds through H shares for expansion, with Everbright Securities International as the sole sponsor [1] Financial Performance - From 2023 to 2024, the company's revenue is projected to grow from 777 million RMB to 802 million RMB, reflecting a growth rate of only 3.18%, significantly lower than the 8.0% compound annual growth rate of the Chinese TIC industry during the same period [2] - In the core business segments, the performance is mixed. The communication and automotive services segment is expected to see a 36.7% year-on-year increase in revenue to 228 million RMB in the first nine months of 2025, while the industrial and facilities services segment is projected to decline by 8.3%, and the consumer and health services segment is expected to decrease by 7.4% [2] - The industrial and facilities services segment, which was once the largest revenue source, accounted for 46.0% of total revenue in 2023 but has seen both revenue shrinkage and a narrowing gross margin due to reduced income from new energy facility services [2] Compliance and Legal Issues - The company has notable deficiencies in compliance operations, posing potential operational risks. From 2023 to the first nine months of 2025, there were continuous shortfalls in social insurance and housing fund contributions, totaling 27 million RMB, 29.8 million RMB, and 26.6 million RMB respectively [4] - The company has confirmed past involvement in legal disputes related to infringement and contract issues, which could lead to financial burdens such as back payments and fines if regulatory actions are taken [5] - The company has engaged 753, 811, and 702 subcontractors in 2023, 2024, and the first nine months of 2025, with total subcontracting costs exceeding 300 million RMB [7] Expansion Plans - The funds raised from the Hong Kong listing are intended for the establishment of laboratories in Indonesia and Brazil, the setup of a 6G sensing laboratory in Hangzhou, AI technology applications, and working capital supplementation [8] - The company's past overseas expansion efforts have not been successful, with the German subsidiary established in 2023 failing to generate significant revenue and the Brazilian subsidiary still in preparation [9] - Despite the planned funding for overseas laboratory bases, the company's overseas revenue decreased from 14.675 million RMB to 13.751 million RMB in the first nine months of 2025, while domestic revenue continues to grow steadily [10] Previous Listing Attempts - The company has previously attempted to apply for A-share listings in 2021 and 2023, both of which did not progress successfully [12]